

# Ronald C Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4593323/publications.pdf>

Version: 2024-02-01

128  
papers

3,664  
citations

186265

28  
h-index

149698

56  
g-index

131  
all docs

131  
docs citations

131  
times ranked

5947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Simultaneous dose and dose rate optimization (SDDRO) of the FLASH effect for pencilâ€beamâ€scanning proton therapy. <i>Medical Physics</i> , 2022, 49, 2014-2025.	3.0	22
2	Evaluation of Telemedicine Use Among US Patients With Newly Diagnosed Cancer by Socioeconomic Status. <i>JAMA Oncology</i> , 2022, 8, 161.	7.1	24
3	Evaluation of the Dose Delivery Consistency and Its Dependence on Imaging Modality and Deformable Image Registration Algorithm in Prostate Cancer Patients. <i>Journal of Medical and Biological Engineering</i> , 2022, 42, 74-86.	1.8	2
4	Patient Decision-Making Factors in Aggressive Treatment of Low-Risk Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	1
5	Minimum-monitor-unit optimization via a stochastic coordinate descent method. <i>Physics in Medicine and Biology</i> , 2022, 67, 015009.	3.0	8
6	Testing the efficacy of a couple-focused, tailored eHealth intervention for symptom self-management among men with prostate cancer and their partners: the study protocol. <i>Trials</i> , 2022, 23, 12.	1.6	2
7	Considerations on Integrating Prostate-Specific Membrane Antigen Positron Emission Tomography Imaging Into Clinical Prostate Cancer Trials by National Clinical Trials Network Cooperative Groups. <i>Journal of Clinical Oncology</i> , 2022, 40, 1500-1505.	1.6	16
8	Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer. <i>European Urology Open Science</i> , 2022, 37, 113-119.	0.4	10
9	Pre-Treatment Staging Imaging in Rectal Cancer: Results From the Quality Oncology Practice Initiative. <i>JCO Oncology Practice</i> , 2022, , OP2100455.	2.9	0
10	An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 278-289.	0.8	4
11	Ruralâ€Urban Disparities in Health Access Factors Over Time: Implications for Cancer Prevention and Health Equity in the Midwest. <i>Health Equity</i> , 2022, 6, 382-389.	1.9	1
12	Racial differences in user experiences and perceived value of electronic symptom monitoring in a cohort of black and white bladder and prostate cancer patients. <i>Quality of Life Research</i> , 2021, 30, 3213-3227.	3.1	12
13	Enhancing survivorship care planning for patients with localized prostate cancer using a couple-focused web-based, mHealth program: the results of a pilot feasibility study. <i>Journal of Cancer Survivorship</i> , 2021, 15, 99-108.	2.9	15
14	Machine learning and statistical prediction of patient quality-of-life after prostate radiation therapy. <i>Computers in Biology and Medicine</i> , 2021, 129, 104127.	7.0	12
15	Feasibility and delivery of patient-reported outcomes in clinical practice among racially diverse bladder and prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 77.e1-77.e8.	1.6	6
16	Adjuvant Versus Early Salvage Radiation Therapy After Radical Prostatectomy for Men With Adverse Pathologic Featuresâ€The Debate Continues. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 839-843.	0.8	3
17	Race and prostate specific antigen surveillance testing and monitoring 5-years after definitive therapy for localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1093-1102.	3.9	2
18	Prostate Stereotactic Body Radiation Therapy: An Overview of Toxicity and Dose Response. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 237-248.	0.8	40

#	ARTICLE	IF	CITATIONS
19	The Impact of Imaging Advances on Prostate Cancer Management: Many Unanswered Questions Remain. Practical Radiation Oncology, 2021, 11, 212-214.	2.1	0
20	Association of Cancer Screening Deficit in the United States With the COVID-19 Pandemic. JAMA Oncology, 2021, 7, 878.	7.1	204
21	Recommendations for including or reviewing patient reported outcome endpoints in grant applications. BMJ, The, 2021, 373, n1367.	6.0	5
22	Receipt of Guideline-Recommended Surveillance in a Population-Based Cohort of Prostate Cancer Patients Undergoing Active Surveillance. International Journal of Radiation Oncology Biology Physics, 2021, 110, 712-715.	0.8	2
23	Underascertainment of Clinically Meaningful Symptoms During Prostate Cancer Radiation Therapy—Does This Vary by Patient Characteristics?. International Journal of Radiation Oncology Biology Physics, 2021, 110, 1122-1128.	0.8	3
24	Understanding Competing Risks. International Journal of Radiation Oncology Biology Physics, 2021, 110, 636-640.	0.8	8
25	Asymmetric multi-task attention network for prostate bed segmentation in computed tomography images. Medical Image Analysis, 2021, 72, 102116.	11.6	14
26	Does Bigger Practice Size Mean Better for Patients and Providers?. International Journal of Radiation Oncology Biology Physics, 2021, 111, 619-621.	0.8	0
27	Editorial: A New Phase for <i>JNCI Cancer Spectrum</i>. JNCI Cancer Spectrum, 2021, 5, pkab006.	2.9	0
28	An adaptive spot placement method on Cartesian grid for pencil beam scanning proton therapy. Physics in Medicine and Biology, 2021, 66, 235012.	3.0	2
29	Randomized Trials and the Goldilocks Problem. European Urology, 2020, 77, 11-13.	1.9	4
30	Educational Material on Prostate Cancer Screening is Overly Complex and Fails to Meet Recommended Layperson Readability Guidelines. Urology, 2020, 135, 1-3.	1.0	5
31	Dosimetric correlations with urinary quality of life in patients receiving post-prostatectomy radiation therapy. Journal of Radiation Oncology, 2020, 9, 97-102.	0.7	0
32	OPTIK: a database for understanding catchment areas to guide mobilization of cancer center assets. Database: the Journal of Biological Databases and Curation, 2020, 2020, .	3.0	3
33	Evaluation of a commercial DIR platform for contour propagation in prostate cancer patients treated with IMRT/VMAT. Journal of Applied Clinical Medical Physics, 2020, 21, 14-25.	1.9	3
34	Analysis of Price Transparency via National Cancer Institute—“Designated Cancer Centers”™ Chagemasters for Prostate Cancer Radiation Therapy. JAMA Oncology, 2020, 6, 409.	7.1	32
35	Associations between prostate cancer—related anxiety and health—related quality of life. Cancer Medicine, 2020, 9, 4467-4473.	2.8	17
36	Asymmetrical Multi-task Attention U-Net for the Segmentation of Prostate Bed in CT Image. Lecture Notes in Computer Science, 2020, 12264, 470-479.	1.3	9

#	ARTICLE	IF	CITATIONS
37	Active Surveillance for Black Men With Low-Risk Prostate Cancer. JAMA - Journal of the American Medical Association, 2020, 324, 1733.	7.4	8
38	Partial Prostate Cancer Treatment for Aggressive Disease—Common Practice. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1035-1037.	0.8	0
39	Prevalence and predictors of probable depression in prostate cancer survivors. Cancer, 2019, 125, 3418-3427.	4.1	32
40	Patient-reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a population-based prospective cohort. Cancer, 2019, 125, 3657-3665.	4.1	9
41	Radiation therapy for prostate cancer: An evolving treatment modality. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 579-581.	1.6	2
42	SBRT for Localized Prostate Cancer: Is it Ready for Take-Off?. International Journal of Radiation Oncology Biology Physics, 2019, 105, 618-620.	0.8	7
43	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Radiotherapy and Oncology, 2019, 141, 208-213.	0.6	42
44	The Impact of the Affordable Care Act on Disparities in Private and Medicaid Insurance Coverage Among Patients Under 65 With Newly Diagnosed Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 25-30.	0.8	13
45	Big Data in Oncology: Toward a Goal of Learning More From Every Patient. Seminars in Radiation Oncology, 2019, 29, 299-301.	2.2	1
46	Reconstructing Tissue Properties From Medical Images With Application in Cancer Screening. IEEE Transactions on Medical Robotics and Bionics, 2019, 1, 6-13.	3.2	0
47	Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer. Journal of the National Medical Association, 2019, 111, 246-255.	0.8	3
48	Patterns and predictors of self-reported clinical diagnosis and treatment for depression in prostate cancer survivors. Cancer Medicine, 2019, 8, 3648-3658.	2.8	11
49	Role of novel imaging in the management of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 611-618.	1.6	14
50	Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer. European Urology, 2019, 76, 391-397.	1.9	11
51	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 33-35.	0.8	8
52	A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. European Urology, 2019, 2, 294-301.	5.4	38
53	Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective Study. International Journal of Radiation Oncology Biology Physics, 2019, 103, 112-115.	0.8	14
54	Comparative Effectiveness of Prostate Cancer Treatment Options: Limitations of Retrospective Analysis of Cancer Registry Data. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1053-1057.	0.8	15

#	ARTICLE	IF	CITATIONS
55	Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis. <i>Gynecologic Oncology</i> , 2018, 148, 349-356.	1.4	50
56	Contemporary Incidence and Outcomes of Prostate Cancer Lymph Node Metastases. <i>Journal of Urology</i> , 2018, 199, 1510-1517.	0.4	31
57	Stereotactic body radiation therapy for high-risk prostate cancer: Not ready. <i>Practical Radiation Oncology</i> , 2018, 8, 203-205.	2.1	1
58	Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture. <i>Clinical Cancer Research</i> , 2018, 24, 2539-2547.	7.0	32
59	Patterns of Care of Node-Positive Prostate Cancer Patients Across the United States: A National Cancer Data Base Analysis. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 35-41.e1.	1.9	4
60	Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 3251-3258.	1.6	129
61	Racial Disparities in Time From Diagnosis to Treatment for Stage I Non-Small Cell Lung Cancer. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky007.	2.9	14
62	Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2018, 15, 1792-1810.	0.6	12
63	Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy. <i>Radiation Oncology</i> , 2018, 13, 17.	2.7	15
64	Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using a Couple-Focused mHealth Symptom Self-Management Program: Protocol for a Feasibility Study. <i>JMIR Research Protocols</i> , 2018, 7, e51.	1.0	9
65	What is the best way to radiate the prostate in 2016?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 59-68.	1.6	31
66	Comparison of Patient Report and Medical Records of Comorbidities. <i>JAMA Oncology</i> , 2017, 3, 1035.	7.1	39
67	Folate-targeted nanoparticle delivery of androgen receptor shRNA enhances the sensitivity of hormone-independent prostate cancer to radiotherapy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1309-1321.	3.3	28
68	Stereotactic Body Radiotherapy for Large Primary Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e851-e854.	1.9	17
69	Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer—Reply. <i>JAMA Oncology</i> , 2017, 3, 281.	7.1	4
70	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1141.	7.4	250
71	Evaluating the Effectiveness of Neoadjuvant Chemotherapy in Reducing Mastectomy for Women With Breast Cancer. <i>JNCI Cancer Spectrum</i> , 2017, 1, pkx004.	2.9	3
72	Aggressive End-of-Life Care for Metastatic Cancer Patients Younger Than Age 65 Years. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	51

#	ARTICLE	IF	CITATIONS
73	Lymph node–positive prostate cancer—From middle child to the new frontier. <i>Cancer</i> , 2017, 123, 387-389.	4.1	0
74	Management of Node-Positive and Oligometastatic Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2017, 27, 79-86.	2.2	10
75	Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer. <i>Practical Radiation Oncology</i> , 2017, 7, e117-e124.	2.1	10
76	Quality of care received and patient–reported regret in prostate cancer: Analysis of a population–based prospective cohort. <i>Cancer</i> , 2017, 123, 138-143.	4.1	25
77	Responding to a Community's Concern. <i>North Carolina Medical Journal</i> , 2017, 78, 357-365.	0.2	2
78	Adoption of Stereotactic Body Radiotherapy for Stage IA Non–Small Cell Lung Cancer Across the United States. <i>JNCI Cancer Spectrum</i> , 2017, 1, pxx003.	2.9	16
79	Reply to J.J. Tosoian et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 4453-4453.	1.6	0
80	Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012. <i>Cancer</i> , 2016, 122, 2234-2241.	4.1	34
81	Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy. <i>Medical Physics</i> , 2016, 43, 6569-6576.	3.0	0
82	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 T <i>Journal of Oncology Practice</i> , 2016, 12, 267-269.	2.5	11
83	In regard to Wu and Vapiwala et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 858-859.	0.8	2
84	Using big data for quality assessment in oncology. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 309-319.	1.4	8
85	Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States. <i>JAMA Oncology</i> , 2016, 2, 1236.	7.1	13
86	Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , 2016, 122, 3069-3074.	4.1	8
87	Neoadjuvant Systemic Therapy Use for Younger Patients with Breast Cancer Treated in Different Types of Cancer Centers Across the United States. <i>Journal of the American College of Surgeons</i> , 2016, 223, 717-728e4.	0.5	19
88	Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2835-2842.	1.6	213
89	Evaluation of the effectiveness of adding androgen deprivation to modern dose–escalated radiotherapy for men with favorable intermediate–risk prostate cancer. <i>Cancer</i> , 2016, 122, 2341-2349.	4.1	14
90	Postprostatectomy Radiotherapy: Whether and How Long to Give Concurrent Androgen Deprivation Therapy. <i>European Urology</i> , 2016, 69, 58-59.	1.9	2

#	ARTICLE	IF	CITATIONS
91	How Will Big Data Impact Clinical Decision Making and Precision Medicine in Radiation Therapy?. International Journal of Radiation Oncology Biology Physics, 2016, 95, 880-884.	0.8	22
92	Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer. American Journal of Men's Health, 2016, 10, 399-407.	1.6	16
93	US radiation oncology practice patterns for posttreatment survivor care. Practical Radiation Oncology, 2016, 6, 50-56.	2.1	16
94	Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 627 T Clinical Oncology, 2016, 34, 2182-2190.	1.6	285
95	Stage at presentation and survival outcomes of patients with Gleason 8â€“10 prostate cancer and low prostate-specific antigen. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e19-119.e26.	1.6	25
96	Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome?. European Urology, 2016, 69, 211-212.	1.9	1
97	Costâ€“effectiveness analysis of neurocognitiveâ€“sparing treatments for brain metastases. Cancer, 2015, 121, 4231-4239.	4.1	26
98	Association Between Certificate of Need Legislation and Radiation Therapy Use Among Elderly Patients With Early Cancers. International Journal of Radiation Oncology Biology Physics, 2015, 91, 448-450.	0.8	4
99	Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. European Urology, 2015, 67, 460-467.	1.9	190
100	Unanticipated hospital admissions during or soon after radiation therapy: Incidence and predictive factors. Practical Radiation Oncology, 2015, 5, e245-e253.	2.1	38
101	Summing it up: An integrative review of studies of cancer survivorship care plans (2006â€“2013). Cancer, 2015, 121, 978-996.	4.1	138
102	Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients. International Journal of Radiation Oncology Biology Physics, 2015, 92, 244-251.	0.8	49
103	Radiotherapy for high-risk prostate cancer. Nature Reviews Urology, 2015, 12, 145-154.	3.8	25
104	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 386.e1-386.e6.	1.6	15
105	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 3436-3448.	1.6	201
106	Adoption of Hypofractionated Radiation Therapy for Breast Cancer After Publication of Randomized Trials. International Journal of Radiation Oncology Biology Physics, 2014, 90, 1001-1009.	0.8	96
107	Cancer Screening Rates in Individuals With Different Life Expectancies. JAMA Internal Medicine, 2014, 174, 1558.	5.1	142
108	Adjuvant and Salvage Radiotherapy After Prostatectomy: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology, 2014, 32, 3892-3898.	1.6	84

#	ARTICLE	IF	CITATIONS
109	Receipt of Guideline-Concordant Treatment in Elderly Prostate Cancer Patients. International Journal of Radiation Oncology Biology Physics, 2014, 88, 332-338.	0.8	24
110	Comparative Effectiveness Research in Oncology: The Promise, Challenges, and Opportunities. Seminars in Radiation Oncology, 2014, 24, 1-4.	2.2	8
111	Associations between patientâ€“provider communication and socio-cultural factors in prostate cancer patients: A cross-sectional evaluation of racial differences. Patient Education and Counseling, 2014, 97, 339-346.	2.2	39
112	Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials. Journal of the National Cancer Institute, 2014, 106, .	6.3	83
113	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Databaseâ€“UNC GOLD. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 32.e1-32.e9.	1.6	8
114	Commentary: Toward safe and high quality care through peer review in radiation oncology: Need for more evidence. Practical Radiation Oncology, 2014, 4, 285-287.	2.1	8
115	Use of Bone Scan During Initial Prostate Cancer Workup, Downstream Procedures, and Associated Medicare Costs. International Journal of Radiation Oncology Biology Physics, 2014, 89, 243-248.	0.8	39
116	Clinical implications of bone scan underuse for patients with high-risk prostate cancer (CaP).. Journal of Clinical Oncology, 2014, 32, 124-124.	1.6	0
117	Population-based analysis of mortality over time in endometrial cancer.. Journal of Clinical Oncology, 2014, 32, 5605-5605.	1.6	0
118	National study to determine the comfort levels of radiation therapists and medical dosimetrists to report errors. Practical Radiation Oncology, 2013, 3, e165-e170.	2.1	11
119	Making Individualized Decisions in the Midst of Uncertainties: The Case of Prostate Cancer and Biochemical Recurrence. European Urology, 2013, 64, 916-918.	1.9	6
120	Comparison of User-Directed and Automatic Mapping of the Planned Isocenter to Treatment Space for Prostate IGRT. International Journal of Biomedical Imaging, 2013, 2013, 1-12.	3.9	0
121	Guideline-Adherent Care vs Quality Care in Cancer Patients: Twins or Distant Cousins?. JAMA Internal Medicine, 2013, 173, 569.	5.1	5
122	Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 952-960.	4.9	54
123	Treatment patterns for patients with localized (T1-T2) penile squamous cell carcinoma in the United States.. Journal of Clinical Oncology, 2013, 31, 332-332.	1.6	0
124	Prevalence of cardiovascular disease (CVD) risk factors and receipt of preventive care among prostate cancer (CaP) survivors in the United States.. Journal of Clinical Oncology, 2013, 31, 185-185.	1.6	0
125	Phase I study of concurrent weekly docetaxel, highâ€“dose intensityâ€“modulated radiation therapy (IMRT) and androgenâ€“deprivation therapy (ADT) for highâ€“risk prostate cancer. BJU International, 2012, 110, E721-6.	2.5	17
126	Impact of Age and Comorbidity on Treatment and Outcomes in Elderly Cancer Patients. Seminars in Radiation Oncology, 2012, 22, 265-271.	2.2	80



#	ARTICLE	IF	CITATIONS
127	Impact of diagnosis and treatment of clinically localized prostate cancer on health-related quality of life for older Americans. <i>Cancer</i> , 2012, 118, 5679-5687.	4.1	60
128	Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial. <i>BJU International</i> , 2012, 110, 1690-1695.	2.5	23